July 6, 2026
“…The stock has been broadly flat over the past month, with a 0.0% 30 day return, but its 22.3% return over the last year and very large 5 year gain of about 3x keep it on many investors’ radars… Bringing… Continue Reading…
April 27, 2026
“President Donald Trump said the U.S. will blockade the Strait of Hormuz after talks to end the Iran war ended without a resolution over the weekend. Trump also said the U.S. Navy will “seek and interdict every vessel in International… Continue Reading…
April 23, 2026
“The stock last closed at CHF 66.10, with returns of 3.3% over 7 days, 6.7% over 30 days, 15.5% year to date, and 108.2% over 1 year. These figures naturally raise questions about how much of the story is already… Continue Reading…
April 12, 2026
“…Pro forma net revenue rose 21% from a year earlier to 18.3 billion reais ($3.7 billion), while pro forma earnings before interest, taxes, depreciation and amortization increased 24% to 10.3 billion reais, the Sao Paulo-based sanitation company said early Saturday.… Continue Reading…
April 12, 2026
“Google launched an AI-design platform, pushing Figma shares down 12% in two days. Figma, which went public in July, reached an agreement last year to use more of Google’s AI services. Figma’s stock is down about 35% this year, as… Continue Reading…
April 12, 2026
“In early April 2026, FuboTV outlined long-term financial targets, including adjusted EBITDA goals for 2026 and 2028 and an expectation of turning free cash flow positive by 2027, alongside executing a 1-for-12 reverse stock split and integrating Disney’s Hulu +… Continue Reading…
April 12, 2026
“People tied to an unnamed U.S. server maker illegally diverted billions in equipment containing Nvidia artificial intelligence chips to China, U.S. prosecutors said. Super Micro said one of the defendants was a co-founder and executive of its company, another was… Continue Reading…
April 7, 2026
“Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide. The stock plummeted on Monday, hitting its lowest level since June 2021. The Danish drugmaker is also navigating… Continue Reading…
Recent Comments